Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis最新文献

Presidential Address: PRESIDENTIAL ADDRESS 总统演说:总统演说

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2008-06-28 DOI: 10.1111/J.1526-0968.1999.00152.PP.X

Rolf Baumbauer

引用次数: 0

Time-course of iodine elimination by hemodialysis in patients with renal failure after angiography. 血管造影后肾功能衰竭患者血液透析消除碘的时间过程。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00469.x

Toshio Shinoda, Toshihiko Hata, Ken-ichi Nakajima, Hiroshi Yoshimoto, Akihiro Niwa

{"title":"Time-course of iodine elimination by hemodialysis in patients with renal failure after angiography.","authors":"Toshio Shinoda, Toshihiko Hata, Ken-ichi Nakajima, Hiroshi Yoshimoto, Akihiro Niwa","doi":"10.1046/j.1526-0968.2002.00469.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00469.x","url":null,"abstract":"The study was designed to examine the time-course of iodine elimination by hemodialysis to determine a desirable duration for dialysis after angiography to prevent contrast media nephropathy (CMN) in patients with renal failure. Reduction rates of iodine by hemodialysis (DRR) of 1 to 3 h and the renal elimination of iodine (RER) for 20 h after hemodialysis were prospectively examined in 8 chronic renal failure (CRF) patients. The mean DRR was 46.6% at 1 h, 65.2% at 2 h, and 75.1% at 3 h, and the mean RER was 49.4% in the CRF patients. Renal function significantly deteriorated in 2 CRF patients after angiography. Plasma iodine was eliminated by more than 80% after 2 h of hemodialysis following angiography, and the subsequent renal elimination in patients with mild-to-moderate renal failure was also examined. There is no need of prophylactic hemodialysis to prevent CMN for these patients when they have no additional risk factors such as a high dose of contrast medium, diabetes mellitus, or severe heart failure. However, 2 h of hemodialysis is desirable immediately after angiography for patients with moderate renal failure and one additional risk factor, and three hours or more of hemodialysis is also desirable for patients with severe renal failure, and for those with moderate renal failure having two or more additional risk factors.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00469.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22135820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis. 狼疮性肾炎肾病综合征应用低密度脂蛋白分离治疗1例。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00458.x

Yuji Kamijo, Yoko Kaneko, Toru Ichikawa, Nobuhiko Kobayashi, Takayuki Koyama, Tetsuji Kakegawa, Hiroshi Kamijo, Keiichi Kono, Satoshi Minami, Naoki Tanaka, Hideo Arakura, Masayuki Hirata, Makoto Higuchi, Kendo Kiyosawa, Kazuhiko Hora

{"title":"A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis.","authors":"Yuji Kamijo, Yoko Kaneko, Toru Ichikawa, Nobuhiko Kobayashi, Takayuki Koyama, Tetsuji Kakegawa, Hiroshi Kamijo, Keiichi Kono, Satoshi Minami, Naoki Tanaka, Hideo Arakura, Masayuki Hirata, Makoto Higuchi, Kendo Kiyosawa, Kazuhiko Hora","doi":"10.1046/j.1526-0968.2002.00458.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00458.x","url":null,"abstract":"Our report discusses a 29 year old female patient with nephrotic syndrome due to lupus nephritis, biopsy-proven World Health Organization classification Types IVb and V that was controlled with low-density lipoprotein (LDL) apheresis. She was initially treated with steroid therapy, including methylprednisolone pulse therapy, and the serological activity of her systemic lupus erythematosus was suppressed. However, her nephrotic state, accompanied by severe hyperlipidemia, persisted despite the steroid therapy. Since we could not obtain her consent to administer immunosuppressants such as cyclophosphamide, we tried to treat her using LDL apheresis (LDL-A). We found that her urine protein excretion, hyperlipidemia, hypoalbuminemia, and renal function improved following the initiation of LDL-A. This suggests that LDL-A may be an effective therapy for nephrotic syndrome due to lupus nephritis through short-term amelioration of hyperlipidemia.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00458.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22136323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Mobilization factors of peripheral blood stem cells in healthy donors. 健康献血者外周血干细胞的动员因子。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00463.x

N Shimizu, T Asai, S Hashimoto, M Narita, M Kobayashi, M Ito, M Onoda, A Yokota, R Cho, C Nakaseko, M Nishimura, Y Saito

{"title":"Mobilization factors of peripheral blood stem cells in healthy donors.","authors":"N Shimizu, T Asai, S Hashimoto, M Narita, M Kobayashi, M Ito, M Onoda, A Yokota, R Cho, C Nakaseko, M Nishimura, Y Saito","doi":"10.1046/j.1526-0968.2002.00463.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00463.x","url":null,"abstract":"As a source of hematopoietic stem cells for transplantation, the use of peripheral blood stem cells (PBSCs) has become routine and comparable to that of the use of bone marrow. Recently, elderly patients with hematological malignancies also have been allowed to receive minitransplantations with nonmyeloablative conditioning regimens under sufficient PBSC infusion. As a result of these minitransplantations, elderly donors have been chosen increasingly from the siblings of elderly patients. We analyzed factors influencing the condition of CD34+ cells in the first days of collection in 49 healthy donors from July 1995 to January 2001. The median dose of recombinant human granulocyte colony-stimulating factor was 8 microg/kg/day (range 8 - 10) over 3 days. The target number of CD34+ cells used in this study was > or = 3 x 10(6) cells/kg of recipient body weight. The median apheresis volume was 12 L. Except for one 60 year old man, we obtained an adequate number of stem cells. In the regression analysis, a negative correlation was seen between donor age and the number of CD34+ cells/kg of recipient body weight per 12 L volume (Y = aX + b; a = -0.07507; b = 6.629996; r = -0.50985; p = 0.000252). Significantly higher apheresis results were obtained in donors younger than 45 years compared with donors 45 years old and older (p < 0.0227). There were no correlations among the number of CD34+ cells, donor body weight, and the number of leukocytes in peripheral blood on the first day of apheresis.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00463.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22135816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. 危重病人持续血液滤过血浆交换去除细胞因子。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00464.x

Hajime Nakae, Yoshihiro Asanuma, Kimitaka Tajimi

{"title":"Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients.","authors":"Hajime Nakae, Yoshihiro Asanuma, Kimitaka Tajimi","doi":"10.1046/j.1526-0968.2002.00464.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00464.x","url":null,"abstract":"The effectiveness of plasma exchange (PE) with continuous hemodiafiltration (CHDF) in the treatment of critically ill patients was evaluated based on changes in cytokine levels. Twenty-six patients with acute hepatic failure were treated with PE (PE group) or PE and CHDF (PE+CHDF group), and the levels of cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-8 were determined before and after treatment. Bilirubin levels were significantly lower after treatment in both the PE and PE+CHDF groups. There were no significant differences in TNF-alpha levels before and after treatment in the PE group, but the TNF-alpha level was significantly lower after treatment in the PE+CHDF group. There were no significant differences in the IL-6 levels before and after treatment in both the PE and PE+CHDF groups. There were no significant differences in IL-8 levels before and after treatment in the PE group, but the IL-8 level was significantly lower after treatment in the PE+CHDF group. PE with CHDF therapy was given to 5 patients with acutely aggravated autoimmune diseases, 2 patients with hemorrhagic shock and encephalopathy syndrome, and 3 patients with thrombotic microangiopathy. The results suggested that PE with CHDF therapy are useful in critically ill patients with suspected hypercytokinemia.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00464.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22135817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 53

A case of acute hepatic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation. 新型血浆置换术治疗急性肝功能不全1例，血浆滤过过桥直至肝移植。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00468.x

Tsuyoshi Mori, Yutaka Eguchi, Tomoharu Shimizu, Yoshihiro Endo, Toyokazu Yoshioka, Kazuyoshi Hanasawa, Tohru Tani

{"title":"A case of acute hepatic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation.","authors":"Tsuyoshi Mori, Yutaka Eguchi, Tomoharu Shimizu, Yoshihiro Endo, Toyokazu Yoshioka, Kazuyoshi Hanasawa, Tohru Tani","doi":"10.1046/j.1526-0968.2002.00468.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00468.x","url":null,"abstract":"A patient with acute hepatic insufficiency induced by a drug presented to our institution, and we performed a novel plasmapheresis that we call plasma dia-filtration (PDF). The patient was a 36 year old woman. She underwent 11 sessions of PDF for a duration of about 9 h for each procedure using the Evacure EC-2A filter together with 20 units of fresh frozen plasma and dialysate simultaneously. Serum levels of total bilirubin and prothrombin time were significantly improved after she underwent each procedure. However, after the third procedure the levels returned to the same level as on the previous day. Encephalopathy improved after the first procedure, and this improvement was maintained until the ninth procedure. The patient prepared to undergo liver transplantation after the tenth procedure because of the development of hepatic coma, but she died of respiratory insufficiency before undergoing the procedure. Accordingly in this case, PDF worked to maintain liver function in acute liver failure and may act as bridge therapy until the patient can undergo liver transplantation.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00468.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22136324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis: report of five cases. 采珠术治疗髓过氧化物酶抗中性粒细胞细胞质抗体相关性血管炎5例报告。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00462.x

Midori Hasegawa, Nahoko Kawamura, Masami Kasugai, Sigehisa Koide, Masamitsu Murase, Sinsuke Asano, Takako Toba, Hiroko Kushimoto, Kazutaka Murakami, Makoto Tomita, Masahiko Shikano, Satoshi Sugiyama

{"title":"Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis: report of five cases.","authors":"Midori Hasegawa, Nahoko Kawamura, Masami Kasugai, Sigehisa Koide, Masamitsu Murase, Sinsuke Asano, Takako Toba, Hiroko Kushimoto, Kazutaka Murakami, Makoto Tomita, Masahiko Shikano, Satoshi Sugiyama","doi":"10.1046/j.1526-0968.2002.00462.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00462.x","url":null,"abstract":"To minimize the adverse effects of high-dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Four patients with rapidly progressive glomerulonephritis (RPGN) and one patient with pulmonary hemorrhage due to MPO-ANCA-associated vasculitis were treated by cytapheresis. The prednisolone (PSL) dose was 0.28 +/- 0.15 mg/kg/day (mean +/- SD) (range 0.18-0.50 g/kg/day). In the 4 RPGN patients, the peak serum creatinine level was 3.7 +/- 1.9 mg/dl (range 1.7 to 5.6 mg/dl). GCAP was performed in 3 RPGN patients and in 1 pulmonary hemorrhage patient. LCAP was performed in 1 RPGN patient. In the 4 RPGN patients, renal function improved after combined therapy with cytapheresis and corticosteroids. In the pulmonary hemorrhage patient, evidence of pulmonary hemorrhage on chest computed tomography scanning diminished after combined therapy with cytapheresis and corticosteroids. Cytapheresis, when combined with a low-dose or intermediate-dose PSL regimen, is effective in the treatment of ANCA-associated vasculitis.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00462.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22135821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Miller Fisher syndrome and plasmapheresis. 米勒费雪综合征和血浆置换。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00466.x

Chiaki Kambara, Hidenori Matsuo, Takayasu Fukudome, Hirofumi Goto, Noritoshi Shibuya

{"title":"Miller Fisher syndrome and plasmapheresis.","authors":"Chiaki Kambara, Hidenori Matsuo, Takayasu Fukudome, Hirofumi Goto, Noritoshi Shibuya","doi":"10.1046/j.1526-0968.2002.00466.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00466.x","url":null,"abstract":"Treatment for Miller Fisher syndrome (MFS) is controversial, and even the natural history and prognosis are not fully understood. We retrospectively reviewed our cases of MFS for the last 3 years. The analysis of 4 MFS cases revealed that we had performed plasmapheresis or additional immunotherapy to each of 4 patients, and their symptoms resolved for up to 50 days after the onset (ataxia improved 20-35 days and ophthalmoplegia for 25-50 days) except for 1 patient, and that Guillain-Barré syndrome had been diagnosed in 1 patient who had developed profound muscle weakness. We also discovered that MFS patients had a deviated T-helper Type-1 (Th1)/T-helper Type-2 (Th2) polarization and that plasmapheresis can shift Th2-dominant status to Th1-dominant status in patients with MFS. Although plasmapheresis may remove humoral factors, including anti-GQ1b, and may induce a shift of the Th1/Th2 cytokine-producing cell balance in peripheral blood, the therapeutic rationale has not yet been established. Therefore, controlled clinical trials are required to show whether plasmapheresis leads to earlier recovery with fewer neurologic deficits in patients with MFS.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00466.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22135822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 31

Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus. 硫酸葡聚糖(Selesorb)血浆分离改善系统性红斑狼疮的血管改变。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00408.x

Norbert Braun, Michael Jünger, Reinhild Klein, Sylvia Gutenberger, Michael Guagnin, Teut Risler

{"title":"Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus.","authors":"Norbert Braun, Michael Jünger, Reinhild Klein, Sylvia Gutenberger, Michael Guagnin, Teut Risler","doi":"10.1046/j.1526-0968.2002.00408.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00408.x","url":null,"abstract":"Apheresis has been effective as rescue therapy in patients with severe, therapy-resistant, systemic lupus erythematosus (SLE). Its benefit in patients with less severe but therapy-resistant SLE is not known. Dextran sulfate apheresis was applied as a rescue therapy for therapy-resistant vasculitic skin lesions in a 30 year old female patient with a 9 year history of SLE in combination with antiphospholipid syndrome and Raynaud's phenomenon. Partial remission was achieved after 9 immunoadsorption sessions, as documented by marked improvement of skin lesions and an increase of capillary density in the nailfold area. Further improvement was noted with maintenance therapy using mycophenolate mofetil. Dextran sulfate apheresis can be applied safely in patients with moderate therapy-resistant SLE disease activity when severe immunodeficiency and cytotoxic adverse effects should be avoided.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00408.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22136326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. 健康志愿者白细胞减少时外周血白细胞和血小板计数的波动。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-12-01 DOI: 10.1046/j.1526-0968.2002.00459.x

Ken Yamaji, Kwangseok Yang, Hiroshi Tsuda, Hiroshi Hashimoto

{"title":"Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers.","authors":"Ken Yamaji, Kwangseok Yang, Hiroshi Tsuda, Hiroshi Hashimoto","doi":"10.1046/j.1526-0968.2002.00459.x","DOIUrl":"https://doi.org/10.1046/j.1526-0968.2002.00459.x","url":null,"abstract":"Leukocytapheresis (LCP) for the treatment of patients with diseases that involve an abnormal autoimmune reaction aims to improve the condition of the patient's pathology and to correct imbalances in immunological regulation mechanisms by removing the responsible leukocytes from the peripheral blood. To clarify the mechanism of therapeutic effect, LCP was conducted in healthy volunteers to investigate changes in peripheral blood leukocyte and platelet counts over time during the treatment. The subjects were 10 healthy male volunteers. LCP was performed once in each volunteer for 3,000 ml of blood volume. The peripheral blood counts decreased significantly, reaching a minimum of 20.0% of the baseline number of leukocytes, 10.1% of the baseline number of neutrophils, and 40.3% of the baseline number of lymphocytes. The number of removed leukocytes was about 6.6 x 10(9) cells, including about 3.5 x 10(9) neutrophils, as well as about 5.0 x 10(11) platelets. After the completion of LCP, the peripheral leukocyte levels increased transiently (overshoot), and at 2 h after the completion of the treatment, they reached 193.4% of the baseline value. Since LCP is capable of reducing the peripheral blood leukocyte count over a short period of time, its impact on peripheral blood is great. In addition, in view of the overshoot phenomenon and the appearance of immature granulocytes, the LCP may affect not only the peripheral blood, but also the bone marrow pool, the marginal pool, and the leukocytes present in the tissues.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1526-0968.2002.00459.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22135815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 45